Whole Blood Transcriptomic and Methylome Signature in Patients with Cushing Disease

This session will provide critical insights into the molecular landscape of aggressive pituitary tumors. Experts will discuss emerging genomic biomarkers that differentiate indolent from aggressive neuroendocrine pituitary tumors, emphasizing their potential for prognostication and targeted therapy. An update on the genetic drivers of corticotroph tumorigenesis will highlight key mutations and epigenetic alterations contributing to tumor growth and recurrence. Advances in transcriptomic and methylomic profiling will also explored, with a focus on whole blood signatures in patients with corticotroph tumors. These systemic biomarkers may serve as non-invasive tools for disease monitoring and therapeutic stratification. The session will underscore the importance of integrating multi-omics approaches to refine the classification and management of pituitary tumors, paving the way for precision medicine strategies in this field. Overall, the discussions will reinforce the role of genetics, genomics and epigenetics in understanding pituitary adenoma pathogenesis and improving patient outcomes.